Avita Medical Strikes Exclusive Deal for Collagen-Based Product
Company Announcements

Avita Medical Strikes Exclusive Deal for Collagen-Based Product

The latest update is out from Avita Medical (RCEL).

AVITA Medical, Inc. has secured an exclusive five-year agreement with Regenity Biosciences to market, sell, and distribute a collagen-based dermal matrix in the U.S. and possibly other regions, pending FDA approval. The partnership includes a financial commitment of up to $5 million from AVITA, with revenue sharing starting at 50% and increasing to 60%. This strategic alliance promises to enhance AVITA’s product portfolio and potentially extend their market reach upon successful clinical outcomes and regulatory clearance.

For detailed information about RCEL stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyAvita Medical price target raised to $12 from $9 at Piper Sandler
TipRanks Auto-Generated NewsdeskAvita Medical Reports Strong Q3 Revenue Growth
TheFlyAvita Medical reports Q3 EPS (62c), consensus (44c)
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App